CANABID-LD is a prospective observational cohort study, with an embedded qualitative component, to examine the impact of clinical trials

Exploring cannabidiol’s impact on behaviour in adults with intellectual disabilities and epilepsy (CANABID-LD)

This study looks at how a medicine called Epidyolex, used for seizures, might also help adults with intellectual disabilities who have certain types of epilepsy (Dravet, Lennox-Gastaut, Tuberous Sclerosis Complex) with challenging behaviours. It follows people already prescribed the medicine.